An immunotherapy drug, Jemperli (dostarlimab) from GSK, has shown unprecedented results in treating locally advanced mismatch repair deficient (dMMR) rectal cancer, achieving a 100% success rate in a clinical trial without the need for surgery or chemotherapy. The trial, presented at the ASCO conference, involved 42 patients who all showed no evidence of disease after treatment. This breakthrough could significantly change the standard of care for this type of bowel cancer.
An immunotherapy drug, dostarlimab (Jemperli), has shown unprecedented results in treating locally advanced mismatch repair deficient (dMMR) rectal cancer, with a 100% success rate in a clinical trial involving 42 patients. This breakthrough could eliminate the need for surgery and chemotherapy for these patients, offering a less invasive treatment option.
Two studies published in the New England Journal of Medicine found that adding immunotherapy drug pembrolizumab to the standard chemotherapy regimen of carboplatin and paclitaxel reduced the risk that patients' advanced or recurrent endometrial cancer would return by up to 70%. The impact was more dramatic in women with a mismatch repair-deficient tumor, a specific type of endometrial cancer. The Food and Drug Administration would need to amend its guidance on using immunotherapy in this way before it's widely implemented as the protocol for treating late-stage endometrial cancer.
